D-0320-2021 Class II Terminated
FDA drug recall D-0320-2021 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Mar 15, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Jun 6, 2023). Affected quantity: 91,211 syringes.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 14, 2021
- Initiation Date
- Mar 15, 2021
- Termination Date
- Jun 6, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 91,211 syringes
Product description
Ganirelix Acetate Injection, 250 mcg/0.5 mL, Sterile Prefilled Syringe, Rx only, Distributor: Ferring Pharmaceuticals, Inc., Parsippany, NJ 07054 USA, Manufactured by: Sun Pharmaceutical Industries Ltd, Halol, Gujarat, India Made in India, NDC 55566-1000-1.
Reason for recall
Failed Impurities/Degradation Specifications
Distribution pattern
NJ
Code information
Lots JKU1212A, JKU1503A, JKU1504A, JKU1505A, JKU1506A, Exp 03/2021; JKU3313A & JKU3314A, Exp 08/2021.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0320-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026